Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)
|
06 November 2020 |
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19
|
03 November 2020 |
New collaboration between Novartis and Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicines
|
02 September 2020 |
Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19
|
17 July 2020 |
Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US
|
02 July 2020 |
Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges
|
24 June 2020 |
Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts
|
22 June 2020 |
Novartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia
|
28 April 2020 |
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program
|
07 April 2020 |
Consignment of 30 million hydroxychloroquine tablets ships to US Department of Health and Human Services
|
31 March 2020 |
Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation
|
27 March 2020 |
Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response
|
23 March 2020 |
Novartis announces broad range of initiatives to respond to COVID-19 Pandemic; Creates USD 20 million global fund to support impacted communities
|
17 March 2020 |
International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa
|
03 March 2020 |
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
|
12 February 2020 |
Sandoz completes acquisition of Aspen's Japanese operations, strengthening its position in world's third largest market for generics and off-patent medicines
|
31 January 2020 |
Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters
|
10 December 2019 |
Novartis announces new strategy to provide innovative medicines to more patients in sub-Saharan Africa
|
19 November 2019 |
Novartis Cosentyx® shows encouraging results versus Humira® from first-of-its-kind head-to-head trial in psoriatic arthritis
|
04 November 2019 |
Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease
|
16 October 2019 |